Hepatocellular Carcinoma Detection via Multi-Gene Methylation Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hepatocellular carcinoma, such as tumor markers and genetic methylation analysis, have insufficient sensitivity and specificity, making early detection challenging, especially in cases of small tumors or false positives.
Innovation Solution
The method involves analyzing the methylation status of specific CpG sites in the promoter regions of ACTG1, EPHA4, and TSC22D1 genes in DNA samples to accurately distinguish cancerous tissues from normal liver tissues or chronic hepatitis/cirrhosis tissues, using techniques like MassARRAY analysis and methylation-specific PCR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If tumor markers (AFP, PIVKA-II) are used for screening hepatocellular carcinoma, then the examination can be performed easily and quickly, but the sensitivity and specificity are insufficient leading to false negatives and false positives
Solution Approach 1:
The invention segments the detection process into multiple independent methylation analysis markers (ACTG1, EPHA4, TSC22D1, WNK2, EMLIN2, TLX3) rather than relying on a single tumor marker. Each marker provides independent detection capability, allowing the system to maintain high screening efficiency while improving overall detection accuracy through multi-marker evaluation
Solution Approach 2:
The invention creates a composite detection system by combining multiple methylation markers with different specificity profiles. This composite approach integrates the strengths of individual markers (ACTG1 for early stage, EPHA4 for specificity, TSC22D1 for sensitivity) to achieve both high screening efficiency and superior detection accuracy simultaneously
2Measurement precision
If the number of genes used as detection markers is increased to improve detection sensitivity, then more markers are needed, but currently only a small number of genes are available for hepatocellular carcinoma detection
Solution Approach 1:
The identified methylation markers (ACTG1, EPHA4, TSC22D1, WNK2, EMLIN2, TLX3) serve multiple functions: they can detect different stages of hepatocellular carcinoma, apply to various patient populations (HBV, HCV, non-viral etiologies), and work across different sample types. This multi-functionality allows a single set of markers to address diverse detection needs without requiring additional marker development
Solution Approach 2:
The invention transitions from traditional single-marker detection to multi-dimensional methylation profiling by analyzing multiple CpG sites across six different genes. This dimensional expansion from one marker to six markers with multiple CpG sites each creates a comprehensive detection landscape that significantly improves sensitivity while maintaining practical applicability
3Measurement precision
If traditional imaging methods (ultrasonic, CT, MRI) are used for definitive diagnosis, then the diagnosis can be made with good accuracy, but the process becomes more complex and requires multiple examinations
Solution Approach 1:
The invention extracts the critical diagnostic information directly from DNA methylation status in blood samples, eliminating the need for complex imaging procedures. By taking out the essential diagnostic capability from the complex imaging workflow and concentrating it in a simple methylation analysis test, the system achieves comparable or superior accuracy with much reduced complexity
Solution Approach 2:
The invention replaces mechanical imaging systems (ultrasonic waves, X-rays, magnetic fields) with a biochemical detection system based on methylation-specific PCR and mass spectrometry. This substitution transitions from complex physical imaging to a simpler molecular analysis approach that achieves definitive diagnosis through direct detection of cancer-specific epigenetic changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the detection sensitivity and specificity for hepatocellular carcinoma, allowing for accurate identification of cancer cells and potentially reducing false positives, thereby aiding in early diagnosis.
Implementation Method 1
analyzing the methylation status of a CpG site in a promoter region of at least one gene selected from ACTG1 (Actin, gamma 1), EPHA4 (EPH receptor A4) and TSC22D1 (TSC22 domain family, member 1)
Data Source
Figure 1~1C
Figure 2
Figure 3~4
AI summary
The present invention relates to a method of analyzing methylation status of a CpG site in a promoter region of at least one gene selected from ACTG1, EPHA4 and TSC22D1 in DNA extracted from a biological sample and determining the presence or absence of a cancer cell derived from hepatocellular carcinoma based on the analysis result. The present invention also relates to a determination marker and kit used for the method.